56 research outputs found
Left Ventricular Mass One Year After Radiofrequency Ablation for Atrial Fibrillation
Myxomas are the most common benign tumors of the heart. The exact etiology of myxomas is unknown and most cases are sporadic. It is well known though that myxomas can develop after cardiac trauma, and that radiofrequency ablation (RFA) for paroxysmal atrial fibrillation (PAF) increases the risk of thrombus or endocarditis in the atrium. The association of RFA and the formation of myxomas is not known. We report a case of a left ventricular myxoma in a patient after RFA
Angiotensin-converting enzyme insertion/deletion polymorphism does not influence the restenosis rate after coronary stent implantation
Background. Experimental studies have shown an activation of the angiotensin-converting enzyme (ACE) system as a response to endothelial injury. Recent publications have elucidated the hypothesis that the ACE gene polymorphism may influence the level of late luminal loss after coronary stent implantation. It is still unclear whether the polymorphism of the angiotensin gene is a major predictor of the extent of neointimal hyperplasia. In this multicenter study, we therefore tested the relationship between the ACE gene polymorphism and the restenosis rate after coronary stent implantation. Methods: As a substudy of the optimization with intracoronary, ultrasound (ICUS) to reduce stent restenosis (OPTICUS) study, we analyzed ACE serum levels and the ACE gene polymorphism in 154 patients at 9 different centers. All patients underwent elective coronary stent implantation in a stenosis of a major coronary vessel. Balloon inflations were repeated until a satisfactory result was achieved in on-line quantitative coronary angiography or ICUS fulfilling the OPTICUS study criteria. After follow-up of 6 months, all patients underwent reangiography tinder identical projections as the baseline procedure. A blinded quantitative analysis of the initial procedure as well as the follow-up examinations were performed by an independent core laboratory. ACE gene polymorphism and ACE serum activity were measured at the 6-month follow-up in a double-blinded setting. Results: With respect to the ACE gene polymorphism, there were three subgroups: DID genotype (48 patients), ID (83 patients) and 11 (23 patients). The subgroups did not differ in regard to age, gender, extent of coronary artery disease, stenosis length, initial degree of stenosis or degree of stenosis after stent implantation. In all, 39 patients (25.3%) had significant restenosis: 12 DD patients (25.0%), 18 ID patients (21.7%) and 9 II patients (39.1%) (odds ratio 2.164, 95% confidence interval 0.853-5.493). We obtained the following results for ACE serum levels: 0.53 mumol/l/s in the DD subgroup, 0.29 mumol/l/s in the ID
Influence of age on the clinical outcomes of coronary revascularisation for the treatment of patients with multivessel de novo coronary artery lesions: sirolimus-eluting stent vs. coronary artery bypass surgery and bare metal stent, insight from the multicentre randomised Arterial Revascularisation Therapy Study Part I (ARTS-I) and Part II (ARTS-II)
peer reviewedAims: We sought to evaluate the prognostic impact of age on the procedural results and subsequent clinical
outcomes in patients with multivessel disease (MVD) treated either by coronary artery bypass surgery (CABG) or
by percutaneous coronary intervention (PCI) with or without drug eluting stents, based on data of the Arterial
Revascularisation Therapies Study (ARTS) part I and part II. The potential influence of age in determining the most
appropriate revascularisation strategy for patients with MVD is largely unknown.
Methods and results: Three year clinical outcome of ARTS I patients randomised to PCI with bare metal stent
(BMS) (n= 600) or CABG (n= 605), and matched patients treated by PCI with sirolimus-eluting stents (SES) in
ARTS II (n= 607) were reviewed according to four age quartiles. Endpoints were measured in terms of major
adverse cardiac and cerebrovascular events MACCE) during hospital stay and up to three years. The frequency of
female, diabetes, hypertension, peripheral vascular disease, pulmonary disease, as well as lesion complexity
increased with age. At three years, MACCE free survival was comparable between patients treated by CABG or
SES PCI, regardless of age quartile. The incidence of MACCE was higher among ARTS I BMS treated patients in
all but the second age quartile. This was primarily related to a higher need for repeat revascularisation among BMS
treated patients. However, age, which emerged as a strong independent predictor of MACCE following CABG
(p<0.005), was not predictive of adverse events following PCI. Conversely, diabetes was the strongest independent
predictor of MACCE among PCI treated patients (p<0.02), but didn’t affect three-year outcomes following CABG.
Conclusions: Age seems to influence the CABG outcome in-hospital but not PCI. PCI-SES could offer lower
immediate risk in patients with MVD and comparable long-term outcome as CABG especially in older patients.
The worst outcome of PCI-BMS group is primarily related to the need for repeat revascularisation. Diabetes is the
most important predictor of MACCE following PCI
Do flavouring compounds contribute to aldehyde emissions in e-cigarettes?
Introduction A recent study identified up to 10,000-fold higher aldehyde
emissions from flavoured compared to unflavoured e-cigarette liquids. We
set to replicate this study and also test similar flavourings with a
new-generation e-cigarette device.
Methods: Three liquids with the highest levels of aldehyde emissions in
the previous study were tested (in standard and sweetened versions)
using the same e-cigarette device and puffing patterns. Additionally,
similar flavourings from a different manufacturer were tested using a
new-generation e-cigarette device. Unflavoured samples were also tested.
Results: Low levels of formaldehyde (8.3-62 mu g/g), acetaldehyde
(12.1-26.0 mu g/g) and acrolein (5.4-19.4 mu g/g) were detected, lower
by up to 589-fold compared to the previous report. Unflavoured liquid
emitted 16.1 mu g/g formaldehyde, 5.6 mu g/g acetaldehyde and 2.4 mu g/g
acrolein, significantly lower compared to 2 liquids for formaldehyde and
1 for acrolein. Emissions from the new-generation device were even
lower. Aldehyde emissions from all flavoured liquids were 79-99.8%
lower than smoking and lower than commonly measured indoor levels and
occupational and indoor safety limits.
Conclusions: The e-cigarettes tested herein emit very low levels of
aldehydes. Some flavourings may contribute to aldehyde emissions, but
the absolute levels were minimal. Validated methods should be used when
analysing e-cigarette emissions
Long-term dual antiplatelet treatment and bleeding complications in diabetic patients treated with drug eluting stent implantation
Dual antiplatelet treatment (DAPLT) for at least 12 months is recommended after drug eluting stent (DES) implantation, but concerns regarding the extended use of this treatment persist due to increased risk of bleeding. In this study are assessed the incidence, correlates, and clinical significance of bleeding complications in diabetic patients after long-term DAPLT post DES implantation. We studied 610 consecutive diabetic patients after DES implantation. The primary end point was the occurrence of any bleeding according to the BARC and TIMI definitions. The incidence of overall bleeding was higher in patients on DAPLT (21.1% vs. 4.4%, p < 0.001), minor/minimal according to the TIMI definition, and type 1 or 2 according to the BARC definition, were more frequently observed in patients on DAPLT (20.3% vs. 3.0%, p < 0.001, 15.6% vs. 2.0%, p < 0.001 and 4.4% vs. 0.5%, p = 0.034, respectively), whereas there was no effect on type 3 (3.5% vs. 2.0%, p = ns). DAPLT was an independent predictor for overall (HR 5.35, 95% CI: 2.69–10.67, p < 0.001), minor (HR 7.45, 95% CI: 3.25–17.12, p < 0.001, for TIMI classification) and type 1 or 2 bleeding (HR 8.17, 95% CI 3.29–20.25, p < 0.001), furthermore smoking was also predictor for overall bleeding (HR 1.65, 95% CI: 1.05–2.61, p = 0.030). Cardiovascular adverse events were not more frequent in patients with bleeding as compared with those without bleeding. Long-term DAPLT in diabetic patients after DES implantation is associated with higher risk of overall and minor but not major bleeding, smoking may have a significant role in the occurrence of bleeding complications
Are Metals Emitted from Electronic Cigarettes a Reason for Health Concern? A Risk-Assessment Analysis of Currently Available Literature
Background: Studies have found that metals are emitted to the electronic cigarette (EC) aerosol. However, the potential health impact of exposure to such metals has not been adequately defined. The purpose of this study was to perform a risk assessment analysis, evaluating the exposure of electronic cigarette (EC) users to metal emissions based on findings from the published literature. Methods: Two studies were found in the literature, measuring metals emitted to the aerosol from 13 EC products. We estimated that users take on average 600 EC puffs per day, but we evaluated the daily exposure from 1200 puffs. Estimates of exposure were compared with the chronic Permissible Daily Exposure (PDE) from inhalational medications defined by the U.S. Pharmacopeia (cadmium, chromium, copper, lead and nickel), the Minimal Risk Level (MRL) defined by the Agency for Toxic Substances and Disease Registry (manganese) and the Recommended Exposure Limit (REL) defined by the National Institute of Occupational Safety and Health (aluminum, barium, iron, tin, titanium, zinc and zirconium). Results: The average daily exposure from 13 EC products was 2.6 to 387 times lower than the safety cut-off point of PDEs, 325 times lower than the safety limit of MRL and 665 to 77,514 times lower than the safety cut-off point of RELs. Only one of the 13 products was found to result in exposure 10% higher than PDE for one metal (cadmium) at the extreme daily use of 1200 puffs. Significant differences in emissions between products were observed. Conclusions: Based on currently available data, overall exposure to metals from EC use is not expected to be of significant health concern for smokers switching to EC use, but is an unnecessary source of exposure for never-smokers. Metal analysis should be expanded to more products and exposure can be further reduced through improvements in product quality and appropriate choice of materials
Tobacco-Specific Nitrosamines in Electronic Cigarettes: Comparison between Liquid and Aerosol Levels
Introduction: Although electronic cigarette (EC) liquids contain low levels of tobacco-specific nitrosamines (TSNAs), studies evaluating the levels emitted to the aerosol are scarce. The purpose of this study was to compare the levels of TSNAs between liquids and generated aerosol. Methods: Three EC liquids were obtained from the market. An additional (spiked) sample was prepared by adding known amounts of standard TSNAs solutions to one of the obtained liquids. N-nitrosonornicotine (NNN), N-nitrosoanatabine (NAT), N-nitrosoanabasine (NAB) and 4-(methylnitrosamino)1-(3-pyridyl)-1-butanone (NNK) were measured. Three 100-puff sets from each liquid were trapped in filter pads and were subsequently analyzed for the presence of TSNAs. The expected levels of TSNAs (calculated based on the liquid consumption) were compared with the measured levels in the aerosol. Results: Only NAB was found at trace levels in two commercial liquids (1.2 and 2.3 ng/g), while the third contained 1.5 ng/g NAB and 7.7 ng/g NNN. The 100-puff sets resulted in 336–515 mg liquid consumption, with no TSNAs being detected in the aerosol. The spiked sample contained 42.0–53.9 ng/g of each of the TSNAs. All TSNAs were detected in the aerosol with the measured levels being statistically similar to the expected amounts. A significant correlation between expected and measured levels of TSNAs in the aerosol was found (r = 0.83, p < 0.001). Conclusion: The findings of this study show that exposure of EC users to TSNAs can be accurately assessed based on the levels present in the liquid, without the need to analyze the aerosol
Origin of Right and Left Coronary Arteries From the Right Sinus of Valsalva as a Common Coronary Trunk
Characteristics, Perceived Side Effects and Benefits of Electronic Cigarette Use: A Worldwide Survey of More than 19,000 Consumers
Background: Electronic cigarette (EC) use has grown exponentially over the past few years. The purpose of this survey was to assess the characteristics and experiences of a large sample of EC users and examine the differences between those who partially and completely substituted smoking with EC use. Methods: A questionnaire was prepared, translated into 10 different languages and uploaded in an online survey tool. EC users were asked to participate irrespective of their current smoking status. Participants were divided according to their smoking status at the time of participation in two subgroups: former smokers and current smokers. Results: In total, 19,414 participants were included in the analysis, with 88 of them (0.5%) reported not being smokers at the time of EC use initiation. Complete substitution of smoking was reported by 81.0% of participants (former smokers) while current smokers had reduced smoking consumption from 20 to 4 cigarettes per day. They were using ECs for a median of 10 months. They initiated EC use with a median of 18 mg/mL nicotine-concentration liquids; 21.5% used higher than 20 mg/mL. Only 3.5% of participants were using 0-nicotine liquids at the time of the survey. Former smokers were highly dependent (Fagerström Test for Cigarette Dependence = 7) and were heavier smokers (21 cigarettes per day when smoking) compared to current smokers. The most important reasons for initiating EC use for both subgroups was to reduce the harm associated with smoking and to reduce exposure of family members to second-hand smoking. Most considered ECs as less harmful than tobacco cigarettes, while 11.0% considered them absolutely harmless. Side effects were reported by more than half of the participants (59.8%), with the most common being sore/dry mouth and throat; side effects were mild and in most cases were subsequently resolved (partially or completely). Participants experienced significant benefits in physical status and improvements in pre-existing disease conditions (including respiratory disease such as asthma and chronic obstructive lung disease). Being former smoker was independently associated with positive effects in health and improvements in disease conditions. Conclusions: The results of this worldwide survey of dedicated users indicate that ECs are mostly used to avoid the harm associated with smoking. They can be effective even in highly-dependent smokers and are used as long-term substitutes for smoking. High levels of nicotine are used at initiation; subsequently, users try to reduce nicotine consumption, with only a small minority using non-nicotine liquids. Side effects are minor and health benefits are substantial, especially for those who completely substitute smoking with EC use. Further population and interventional studies are warranted
- …